Abbott SCSPENDING
Nevro SCSPENDING
Cyclosporiasis OutbreakPENDING
Dupixent CTCLNEW MDL
Boston Sci. SCSNEW MDL
AI Chatbot Harm
NEWMONITOR
Roundup
ACTIVE
AFFF
ACTIVE
Depo-Provera
QUIET
Talc
QUIET
PFAS
ACTIVE
NEC Formula
ACTIVE
Bard Hernia Mesh
QUIET
Covidien Hernia Mesh
ACTIVE
Camp Lejeune
ACTIVE
Paraquat
ACTIVE
Social Media
ACTIVE
PowerPort
ACTIVE
AngioDynamics Port
ACTIVE
EtO Sterilization
ACTIVE
Hair Relaxer
ACTIVE
Paragard
ACTIVE
Suboxone Teeth
ACTIVE
Uber Assault
ACTIVE
Lyft Assault
ACTIVE
Ozempic Gastroparesis
ACTIVE
Ozempic NAION
MONITOR
Church Abuse
ACTIVE
1,4-Dioxane
MONITOR
Hotel Trafficking
ACTIVE
Boy Scouts
QUIET
LDS Abuse
ACTIVE
Keytruda
ACTIVE
Tylenol
ACTIVE
Assembly of God
ACTIVE
Video Game Addiction
ACTIVE
CA Women's Prisons
ACTIVE
Zantac
ACTIVE
ByHeart Formula
MONITOR
Cartiva
MONITOR
Roblox
ACTIVE
Sports Betting
MONITOR
Baby Food Metals
QUIET
Benzene Litigation
ACTIVE
Discord Abuse
ACTIVE
Social Media Sextortion
MONITOR
UPF Litigation
MONITOR
47Tracked
28Active
3Pending
Navigation
Abbott SCSPENDING
Nevro SCSPENDING
Cyclosporiasis OutbreakPENDING
Dupixent CTCLNEW MDL
Boston Sci. SCSNEW MDL
AI Chatbot Harm
NEWMONITOR
Roundup
ACTIVE
AFFF
ACTIVE
Depo-Provera
QUIET
Talc
QUIET
PFAS
ACTIVE
NEC Formula
ACTIVE
Bard Hernia Mesh
QUIET
Covidien Hernia Mesh
ACTIVE
Camp Lejeune
ACTIVE
Paraquat
ACTIVE
Social Media
ACTIVE
PowerPort
ACTIVE
AngioDynamics Port
ACTIVE
EtO Sterilization
ACTIVE
Hair Relaxer
ACTIVE
Paragard
ACTIVE
Suboxone Teeth
ACTIVE
Uber Assault
ACTIVE
Lyft Assault
ACTIVE
Ozempic Gastroparesis
ACTIVE
Ozempic NAION
MONITOR
Church Abuse
ACTIVE
1,4-Dioxane
MONITOR
Hotel Trafficking
ACTIVE
Boy Scouts
QUIET
LDS Abuse
ACTIVE
Keytruda
ACTIVE
Tylenol
ACTIVE
Assembly of God
ACTIVE
Video Game Addiction
ACTIVE
CA Women's Prisons
ACTIVE
Zantac
ACTIVE
ByHeart Formula
MONITOR
Cartiva
MONITOR
Roblox
ACTIVE
Sports Betting
MONITOR
Baby Food Metals
QUIET
Benzene Litigation
ACTIVE
Discord Abuse
ACTIVE
Social Media Sextortion
MONITOR
UPF Litigation
MONITOR
47Tracked
28Active
3Pending
LexGenius Logo
LexGeniusYour Edge in Mass Litigation
PricingDaily DocketTrack litigations freeSign in
LexGenius

LexGenius

Your Edge in Mass Litigation

DisclaimerAcceptable UseTermsPrivacyCookie PolicySupport

© 2026 LexGenius. All rights reserved.

Active MDL17 eventsMedical Device

Paragard

Medical Device · claims that copper IUD arms fractured during removal and caused complications

Defendant

Teva Pharmaceuticals USA, Inc.

MDL / Track

MDL 2974

N.D. Ga.

Judge

Judge Leigh Martin May

Plaintiffs

roughly 3,966 pending (3,926 per JPML's March 2, 2026 report, plus ~40 new filings tracked since)

Bellwether / Trial

Defense verdict for Teva (Feb. 4, 2026, Rickard v. Teva)

Settlement Status

  • No global settlement
  • no settlement fund
  • no claim deadline
Home/Torts/ParaGard
SharePost on XShare on BlueskyShare on LinkedInShare on FacebookEmail

Track litigations for free. Save this matter, capture notes, and monitor live signals.

Sign in
← Torts Case overview Litigation status Geographic exposure Key defendants Timeline Statute of limitations Live activity Leadership News PubMed openFDA Court filings

Case overview

The Paragard IUD MDL (No. 2974, N.D. Ga., Judge Leigh Martin May) remains in active bellwether posture after the first trial ended in a defense verdict for Teva on February 4, 2026. The court postponed remaining bellwether trials to later in 2026 following that verdict; over 4,000 cases are pending with no global settlement reached. Plaintiffs allege the copper IUD's polyethylene arms become brittle during implantation and fracture during standard removal, leaving embedded fragments requiring surgical retrieval.

Causation Theory

Plaintiffs' causation theory centers on polyethylene arm embrittlement: the plastic frame loses flexibility over years of implantation, causing fracture when traction is applied during removal rather than flexing back into the device body. The FDA received over 7,000 adverse event reports of Paragard breakage, with more than 700 incidents reported in the first half of 2024 alone. A 2021 FDA safety review acknowledged that retained fragments carry "unknown consequences" and that breakage "can subject patients to risk and cause anxiety," resulting only in a June 2024 label update directing providers to assess for embedment and consider imaging when gentle removal fails.

Case Management Orders

Litigation status

MDL 2974 remains in active bellwether posture before Judge Leigh Martin May in the Northern District of Georgia. The first bellwether trial ended in a defense verdict for Teva on February 4, 2026 (Rickard v. Teva); remaining bellwethers were postponed to fall 2026 to allow parties to absorb the trial record and complete expert discovery. Case management orders govern Plaintiff Fact Sheet and Defendant Fact Sheet obligations.

MDL Track

MDL 2974

N.D. Ga.

Paragard IUD products liability

3,926 pending

State Court Activity

State court filings continue in NY, CA, IL and other jurisdictions

MDL 2974 Leadership

Plaintiff Leadership

Co-Lead Counsel

Erin K Copeland

Fibich, Leebron, Copeland & Briggs

ecopeland@fibichlaw.com713-231-5961

Timothy Clark

Rosenfeld Injury Lawyers LLC

info@rosenfeldinjurylaw.com888-424-5757

Liaison Counsel

C. Andrew Childers

Childers, Schlueter & Smith, LLC

AChilders@cssfirm.com404-419-9500

Geographic exposure

Approximately 3,595-3,926 cases pending in MDL 2974 as of mid-2026. FDA MAUDE database contains 7,000+ breakage adverse events with 6,000 serious classifications. Device on market since 1984; Teva manufactured 1984-November 2017, CooperSurgical 2017-present. Both manufacturers named in most complaints. No global settlement reached; first bellwether trial (Feb. 2026) returned defense verdict; second bellwether rescheduled fall 2026.

  • Buffalo, New York

    CooperSurgical manufacturing facility — sole Paragard production site since November 2017 acquisition from Teva. FDA 2022 and 2024 inspections found failures to 'adequately investigate breakage complaints' and inadequate corrective action plans; seven of 11 CAPAs remained deficient as of 2024 inspection. Source: Spotlight on America analysis of FDA inspection records (Aug. 2024).

  • Alabama

    Statute-of-limitations dismissals: Judge Leigh Martin May ruled SOL clock starts at IUD breakage moment, not later complications. 2025 ruling dismissed cases from Alabama, Idaho, Michigan, Mississippi, New York, Virginia on this basis. Source: MDL 2974 case management orders, N.D. Ga.

  • Idaho

    SOL dismissal state — Judge May 2025 ruling held injury occurs at breakage, not discovery. Source: MDL 2974 case management orders, N.D. Ga.

  • Michigan

    SOL dismissal state — 2025 ruling held breakage moment triggers clock. Source: MDL 2974 case management orders, N.D. Ga.

  • Mississippi

    SOL dismissal state — 2025 ruling. Source: MDL 2974 case management orders, N.D. Ga.

  • New York

    SOL dismissal state per 2025 ruling. Original Teva manufacturing site location (Buffalo facility). Source: MDL 2974 case management orders, N.D. Ga.; FDA inspection records.

  • Virginia

    SOL dismissal state — 2025 ruling held breakage moment triggers clock. Source: MDL 2974 case management orders, N.D. Ga.

  • Georgia

    SOL survival state — plaintiffs successfully argued concealment extended deadline. MDL 2974 venue (N.D. Ga., Judge Leigh Martin May). Direct filing order active. Source: MDL 2974 administrative orders.

  • Illinois

    SOL survival state — concealment arguments accepted by MDL court. Source: MDL 2974 case management orders.

  • North Carolina

    SOL survival state — concealment arguments accepted. Source: MDL 2974 case management orders.

Key defendants

Teva Pharmaceuticals USA, Inc.

Role: Manufacturer

Core defendant in MDL 2974. Filed motion to dismiss 236 time-barred cases Sept. 2024; actively contesting statute of limitations/repose. Parent Teva Pharmaceutical Industries Ltd. disclosed July 2023.

CooperSurgical, Inc.

Role: Manufacturer

Co-defendant with Teva. Joined dismissal motion targeting stale claims. Corporate parent The Cooper Companies, Inc. disclosed. Withdrawal of opposition to CTO-58 filed Aug. 2023.

Teva Women's Health, LLC

Role: Manufacturer

Named in master complaint; successor to Teva Women's Health, Inc. (terminated from docket April 2021). Active in bellwether discovery per Oct. 2024 orders.

DefendantRoleIntelligence Note
Teva Pharmaceuticals USA, Inc.ManufacturerCore defendant in MDL 2974. Filed motion to dismiss 236 time-barred cases Sept. 2024; actively contesting statute of limitations/repose. Parent Teva Pharmaceutical Industries Ltd. disclosed July 2023.
CooperSurgical, Inc.ManufacturerCo-defendant with Teva. Joined dismissal motion targeting stale claims. Corporate parent The Cooper Companies, Inc. disclosed. Withdrawal of opposition to CTO-58 filed Aug. 2023.
Teva Women's Health, LLCManufacturerNamed in master complaint; successor to Teva Women's Health, Inc. (terminated from docket April 2021). Active in bellwether discovery per Oct. 2024 orders.

Timeline

  1. 2026-04

    Second Bellwether Rescheduled to Fall 2026

    MDL 2974 Judge Leigh Martin May postpones second bellwether trial to Fall 2026 following defense verdict in first trial. MDL contains 3,982 active cases. Richard v. CooperSurgical, MDL 2974, N.D. Ga.

  2. 2026-02

    First Bellwether Ends in Defense Verdict

    Jury returns defense verdict in Richard v. CooperSurgical, first MDL 2974 bellwether trial. Jury found Paragard design not defective and injuries not caused by device. Trial began January 20, 2026. MDL 2974, N.D. Ga.

  3. 2025-10

    Bellwether Trial Order Finalized

    Judge May issues final bellwether trial order setting Richard v. CooperSurgical for January 20, 2026. Second and third bellwethers initially scheduled for March 3 and May 11, 2026. MDL 2974, N.D. Ga.

  4. 2025-07

    Court Sets Key Litigation Deadlines

    Judge May establishes deadlines for expert discovery and dispositive motions ahead of bellwether trials. MDL 2974 case count approaches 3,500. N.D. Ga.

  5. 2022-10

    Study Shows Elevated Breakage Risk

    Medical study published October 31, 2022 documents higher Paragard breakage risk during removal. Study cited in MDL 2974 complaints as scientific basis for design defect claims.

  6. 2021

    FDA Initiates IUD Safety Review

    FDA initiates safety review of IUD breakage following volume of adverse event reports. Review results in 2019 label update warning of arm breakage risk. No recall issued. FDA regulatory action.

  7. 2020-12

    MDL 2974 Created for Paragard Cases

    Judicial Panel on Multidistrict Litigation consolidates federal Paragard cases in MDL 2974 before Judge Leigh Martin May in Northern District of Georgia. JPML Transfer Order.

  8. 2017-09

    CooperSurgical Acquires Paragard

    CooperSurgical purchases Paragard from Teva Pharmaceuticals, becoming co-defendant in subsequent litigation. Ownership transfer completed September 11, 2017.

Statute of limitations

MDL 2974 (In re: Paragard IUD Products Liability Litigation), Judge Leigh Martin May, N.D. Ga. Defendants' Sept. 12, 2024 motion seeks dismissal of 236 cases across 11 states, arguing accrual at device fracture/removal—not subsequent injury discovery. First bellwether trial reset to Jan. 20, 2026 per sources. Intake must prioritize: (1) exact removal/fracture date over symptom onset; (2) state of filing vs. state of injury. No global settlement per sources; individual case viability increasingly SOL-dependent.

⚠ 7 states with critical SOL — act immediately

⚠Alabama

2 years from injury

Rule: Accrual tied to removal surgery date per defendants' Sept. 2024 motion; discovery rule disputed

Discovery: Defendants arguing clock starts at fracture/removal, not later discovery of injury

Among 11 states in Sept. 12, 2024 MDL 2974 dismissal motion targeting 236 cases; motion status unclear from sources

⚠Michigan

3 years from injury

Rule: Product liability claims; defendants arguing device fracture constitutes injury triggering accrual

Discovery: Statutory discovery rule exists but actively contested in MDL

Targeted in Sept. 2024 MDL dismissal motion; intake must screen for removal/fracture date

⚠New York

3 years from injury

Rule: Courts apply discovery rule but defendants challenging in MDL 2974

Discovery: Under active litigation; defendants asserting fracture date controls

Included in 236-case dismissal motion; risk of dismissal if filed more than 3 years post-removal/fracture

⚠Texas

2 years from injury

Rule: Product liability accrual at injury occurrence; defendants arguing strict accrual at fracture/removal

Discovery: Defendants pressing removal-date accrual in pending motion

Among 11 states in Sept. 2024 MDL dismissal motion; 2-year window creates elevated urgency

⚠Tennessee

1 year from injury

Rule: Shortest SOL among active MDL states; defendants pressing removal-date accrual

Discovery: Minimal; statutory discovery provision contested

1-year SOL plus inclusion in dismissal motion creates highest intake risk; cases likely time-barred if removal >1 year ago

⚠North Carolina

3 years from injury

Rule: Product liability with discovery rule; defendants arguing fracture date triggers accrual

Discovery: Contested in MDL 2974

Targeted in Sept. 2024 dismissal motion; screen for removal/fracture date

⚠Georgia

2 years from injury

Rule: MDL venue state with active SOL challenges; defendants asserting removal surgery date controls

Discovery: Discovery rule disputed in pending motion

MDL 2974 situs (N.D. Ga., Judge Leigh Martin May); dismissal motion includes Georgia cases

StateSOLRuleDiscovery RuleNotes
⚠Alabama2 years from injuryAccrual tied to removal surgery date per defendants' Sept. 2024 motion; discovery rule disputedDefendants arguing clock starts at fracture/removal, not later discovery of injuryAmong 11 states in Sept. 12, 2024 MDL 2974 dismissal motion targeting 236 cases; motion status unclear from sources
⚠Michigan3 years from injuryProduct liability claims; defendants arguing device fracture constitutes injury triggering accrualStatutory discovery rule exists but actively contested in MDLTargeted in Sept. 2024 MDL dismissal motion; intake must screen for removal/fracture date
⚠New York3 years from injuryCourts apply discovery rule but defendants challenging in MDL 2974Under active litigation; defendants asserting fracture date controlsIncluded in 236-case dismissal motion; risk of dismissal if filed more than 3 years post-removal/fracture
⚠Texas2 years from injuryProduct liability accrual at injury occurrence; defendants arguing strict accrual at fracture/removalDefendants pressing removal-date accrual in pending motionAmong 11 states in Sept. 2024 MDL dismissal motion; 2-year window creates elevated urgency
⚠Tennessee1 year from injuryShortest SOL among active MDL states; defendants pressing removal-date accrualMinimal; statutory discovery provision contested1-year SOL plus inclusion in dismissal motion creates highest intake risk; cases likely time-barred if removal >1 year ago
⚠North Carolina3 years from injuryProduct liability with discovery rule; defendants arguing fracture date triggers accrualContested in MDL 2974Targeted in Sept. 2024 dismissal motion; screen for removal/fracture date
⚠Georgia2 years from injuryMDL venue state with active SOL challenges; defendants asserting removal surgery date controlsDiscovery rule disputed in pending motionMDL 2974 situs (N.D. Ga., Judge Leigh Martin May); dismissal motion includes Georgia cases

Live intelligence

AI litigation brief

Paragard remains active mdl with 17 current signals in the accepted feed.

Overview

MDL 2974 remains in active bellwether posture before Judge Leigh Martin May in the Northern District of Georgia. The first bellwether trial ended in a defense verdict for Teva on February 4, 2026 (Rickard v. Teva); remaining bellwethers were postponed to fall 2026 to allow parties to absorb the trial record and complete expert discovery. Case management orders govern Plaintiff Fact Sheet and Defendant Fact Sheet obligations.

Key developments

  • PACER court filing on Dec 31: Paragard IUD Products Liability Litigation
  • Cureus news on Jul 17: Hysteroscopic Retrieval of Retained and Fractured Copper Intrauterine Devices: A Case Series of Three Patients and Literature Review - Cureus
  • PubMed research on Jun 8: Uterine Perforation With Extrauterine Intrauterine Device (IUD) Migration Following Blunt Abdominal Trauma: A Case Report.

Trajectory

Court filings and press coverage are both active in MDL 2974, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.

Editorial intelligence

MDL 2974 should stay on the lead docket watch because it is the primary consolidation vehicle for Paragard.

Generated Aug 12, 2026, 2:00 AM UTC

17 events detected

Google News (10)

  • Hysteroscopic Retrieval of Retained and Fractured Copper Intrauterine Devices: A Case Series of Three Patients and Literature Review - Cureus

    CureusJul 17, 2026, 7:23 AM UTC
  • Paragard IUD MDL Judge Trims Claims For 2nd Bellwether Plaintiff - Mealey's

    Mealey'sJul 2, 2026, 12:06 PM UTC
  • IUD Lawsuit 2026: Settlement Amounts & Who Qualifies - LawFold.com

    LawFold.comMay 1, 2026, 7:00 AM UTC
  • After First Paragard IUD Bellwether Trial, Georgia Judge Considers Revising Bellwether Plan - Law.com

    Law.comFeb 17, 2026, 8:00 AM UTC
  • Teva Wins Jury Verdict in First Paragard IUD Bellwether Trial - Bloomberg Law News

    Bloomberg Law NewsFeb 5, 2026, 8:00 AM UTC
  • Teva Wins 1st Paragard IUD Bellwether Trial - Law360

    Law360Feb 4, 2026, 8:00 AM UTC
  • Teva prevails in first U.S. jury trial over Paragard IUD injury claims - Reuters

    ReutersFeb 4, 2026, 8:00 AM UTC
  • Teva's Inconsistent Args In IUD Trial 'Troubling,' Judge Says - Law360

    Law360Jan 21, 2026, 8:00 AM UTC
  • What Happens if an IUD Breaks? - The Cut

    The CutJan 20, 2026, 8:00 AM UTC
  • What Happens if an IUD Breaks? - The Cut

    The CutJan 20, 2026, 8:00 AM UTC
StudyPubMed
Detected Aug 12, 2026, 2:09 AM UTC

Uterine Perforation With Extrauterine Intrauterine Device (IUD) Migration Following Blunt Abdominal Trauma: A Case Report.

Cureus • Poventud Y • PMID 42266549 • Case Reports.

Confidence 74%Published Jun 8, 2026, 12:00 AM UTCSource →

No recent FDA signals. Monitoring is active — this section updates automatically.

PACERJPMLmdl-2974-stubDec 31, 2099, 12:00 AM UTC

Paragard IUD Products Liability Litigation

PACER docket filed in JPML: The plaintiffs are suing a group of pharmaceutical and medical device companies over the ParaGard Intrauterine Device (IUD), which they claim is prone to breaking during removal, often at the arms, causing severe injuries that sometimes require surgical removal of the fragments. They allege that the

COURTLISTENERAug 12, 2026, 2:07 AM UTC

Plaintiff Fact Sheet — MDL No. 2974

This document is a Plaintiff Fact Sheet (PFS) for the Paragard IUD MDL, requiring each plaintiff to complete it under oath with true and correct information.

COURTLISTENERAug 12, 2026, 2:07 AM UTC

Defendant Fact Sheet — Paragard IUD MDL

gand_html

This document is a Defendant Fact Sheet (DFS) template for the Paragard IUD MDL, requiring defendants to complete and serve it under oath per Case Management Order requirements.

PACERGAND1:26-cv-04364Aug 3, 2026, 12:00 AM UTC

Paragard IUD Products Liability Litigation

PACER docket entry from GAND: COMPLAINT with Jury Demand filed by Desiree Martinez. (Filing fee $405, receipt number AGANDC-15431170) (Attachments: # 1 Civil Cover Sheet)(mrg) Please visit our website at http://www.gand.uscourts.gov/commonly-used-forms to obtain Pretrial Instructions and Pretrial Associated Forms which includes

PACERGAND1:26-cv-04108Jul 21, 2026, 12:00 AM UTC

Paragard IUD Products Liability Litigation

PACER docket entry from GAND: SHORT FROM COMPLAINT with Jury Demand filed by Andrea Edman. Direct File MDL-USDC Southern District of New York (Filing fee $405, receipt number AGANDC-15400480) (Attachments: # 1 Civil Cover Sheet)(bmr) Please visit our website at http://www.gand.uscourts.gov/commonly-used-forms to obtain Pretrial

PACERGAND1:26-cv-03992Jul 17, 2026, 12:00 AM UTC

Paragard IUD Products Liability Litigation

PACER docket entry from GAND: COMPLAINT Receipt No: ACACDC-41546820 - Fee: $405, filed by plaintiff Leah Pepper. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet) (Attorney Conor R Nideffer added to party Leah Pepper(pty:pla))(Nideffer, Conor) [Transferred from California Central on 7/17/2026.] (Entered: 02/19/2026)

Audit normalization notes

  • Normalized a source-site outlier template into the canonical detail-page section set.

Workbench

Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.

LexGenius Ranking

88Score

Court, news, and regulatory activity are elevated

Evidence16 / 20
Momentum20 / 20
Exposure16 / 20
Regulatory16 / 20
Legal20 / 20

Monitoring

Live

monitoring

Last: Aug 12, 2026, 2:00 AM UTC

Next: —

Source Monitoring

PACER

1m 15s

PACER

2m 15s

Google News

1m 15s

MAUDE

11m 15s

PubMed

26m 15s

Event feed

17

events detected

Google NewsPACERPubMed

AI Brief

Paragard remains active mdl with 17 current signals in the accepted feed.

Overview

MDL 2974 remains in active bellwether posture before Judge Leigh Martin May in the Northern District of Georgia. The first bellwether trial ended in a defense verdict for Teva on February 4, 2026 (Rickard v. Teva); remaining bellwethers were postponed to fall 2026 to allow parties to absorb the trial record and complete expert discovery. Case management orders govern Plaintiff Fact Sheet and Defendant Fact Sheet obligations.

Key developments

PACER court filing on Dec 31: Paragard IUD Products Liability Litigation. ‖ Cureus news on Jul 17: Hysteroscopic Retrieval of Retained and Fractured Copper Intrauterine Devices: A Case Series of Three Patients and Literature Review - Cureus. ‖ PubMed research on Jun 8: Uterine Perforation With Extrauterine Intrauterine Device (IUD) Migration Following Blunt Abdominal Trauma: A Case Report..

Generated Aug 12, 2026, 2:00 AM UTC

Tracked MDLs

MDL 2974

N.D. Ga.

Paragard IUD products liability

← Previous

Hair Relaxer

Tracks chemical hair-relaxer litigation, product safety reporting, and emerging health literature.

Next →

Suboxone Teeth

Tracks dental-injury litigation, drug-safety notices, and clinical reporting related to Suboxone use.